• Assessment of white matter hyperintensity severity using multimodal magnetic resonance imaging. 
  Parent O, Bussy A, Devenyi GA, Dai A, Costantino M, Tullo S, Salaciak A, Bedford S, Farzin S, Béland ML, Valiquette V, Villeneuve S, Poirier J, Tardif CL, Dadar M; PREVENT-AD Research Group; Chakravarty MM.
  Brain Commun. 2023 Oct 19;5(6):fcad279. doi: 10.1093/braincomms/fcad279. eCollection 2023. PMID: 37953840 
• Sex differences in longitudinal changes of episodic memory-related brain activity and cognition in cognitively unimpaired older adults with a family history of Alzheimer’s disease. 
  Samson AD, Rajagopal S, Pasvanis S, Villeneuve S; PREVENT-AD Research Group; McIntosh AR, Rajah MN.
  Neuroimage Clin. 2023;40:103532. doi: 10.1016/j.nicl.2023.103532. Epub 2023 Oct 29. PMID: 37931333
• Adverse and compensatory neurophysiological slowing in Parkinson’s disease. 
  Wiesman AI, da Silva Castanheira J, Degroot C, Fon EA, Baillet S; PREVENT-AD Research Group; Network QP.
  Prog Neurobiol. 2023 Dec;231:102538. doi: 10.1016/j.pneurobio.2023.102538. Epub 2023 Oct 11. PMID: 37832713
• A prognostic risk score for development and spread of chronic pain. 
  Tanguay-Sabourin C, Fillingim M, Guglietti GV, Zare A, Parisien M, Norman J, Sweatman H, Da-Ano R, Heikkala E; PREVENT-AD Research Group; Perez J, Karppinen J, Villeneuve S, Thompson SJ, Martel MO, Roy M, Diatchenko L, Vachon-Presseau E.
  Nat Med. 2023 Jul;29(7):1821-1831. doi: 10.1038/s41591-023-02430-4. Epub 2023 Jul 6. PMID: 37414898 
• Longitudinal blood biomarker trajectories in preclinical Alzheimer’s disease. 
  Yakoub Y, Ashton NJ, Strikwerda-Brown C, Montoliu-Gaya L, Karikari TK, Kac PR, Gonzalez-Ortiz F, Gallego-Rudolf J, Meyer PF, St-Onge F, Schöll M, Soucy JP, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; PREVENT-AD Research Group.
  Alzheimers Dement. 2023 Dec;19(12):5620-5631. doi: 10.1002/alz.13318. Epub 2023 Jun 9. PMID: 37294682
• Resting-state MRI functional connectivity as a neural correlate of multidomain lifestyle adherence in older adults at risk for Alzheimer’s disease. 
  Ai M, Morris TP, Zhang J, de la Colina AN, Tremblay-Mercier J, Villeneuve S, Whitfield-Gabrieli S, Kramer AF, Geddes MR; PREVENT-AD Research Group.
  Sci Rep. 2023 May 9;13(1):7487. doi: 10.1038/s41598-023-32714-1. PMID: 37160915
• Aberrant neurophysiological signaling associated with speech impairments in Parkinson’s disease. 
  Wiesman AI, Donhauser PW, Degroot C, Diab S, Kousaie S, Fon EA, Klein D, Baillet S; PREVENT-AD Research Group; Quebec Parkinson Network.
  NPJ Parkinsons Dis. 2023 Apr 14;9(1):61. doi: 10.1038/s41531-023-00495-z. PMID: 37059749 
• Sex-specific relationships between obesity, physical activity, and gray and white matter volume in cognitively unimpaired older adults. 
  Intzandt B, Sanami S, Huck J; PREVENT-AD Research group; Villeneuve S, Bherer L, Gauthier CJ.
  Geroscience. 2023 Jun;45(3):1869-1888. doi: 10.1007/s11357-023-00734-4. Epub 2023 Feb 13. PMID: 36781598 
• Characterization of the contactin 5 protein and its risk-associated polymorphic variant throughout the Alzheimer’s disease spectrum. 
  Dauar MT, Labonté A, Picard C, Miron J, Rosa-Neto P, Zetterberg H, Blennow K, Villeneuve S, Poirier J.
  Alzheimers Dement. 2023 Jul;19(7):2816-2830. doi: 10.1002/alz.12868. Epub 2022 Dec 30. PMID: 36583624
• Sex differences in associations between APOE ε2 and longitudinal cognitive decline. 
  Wood ME, Xiong LY, Wong YY, Buckley RF, Swardfager W, Masellis M, Lim ASP, Nichols E, Joie R, Casaletto KB, Kumar RG, Dams-O’Connor K, Palta P, George KM, Satizabal CL, Barnes LL, Schneider JA, Binet AP, Villeneuve S, Pa J, Brickman AM, Black SE, Rabin JS; ADNI and Prevent-AD Research Groups.
  Alzheimers Dement. 2023 Oct;19(10):4651-4661. doi: 10.1002/alz.13036. Epub 2023 Mar 30. PMID: 36994910

• Association of Elevated Amyloid and Tau Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease Symptoms in Older Adults Without Cognitive Impairment. 
  Strikwerda-Brown C, Hobbs DA, Gonneaud J, St-Onge F, Binette AP, Ozlen H, Provost K, Soucy JP, Buckley RF, Benzinger TLS, Morris JC, Villemagne VL, Doré V, Sperling RA, Johnson KA, Rowe CC, Gordon BA, Poirier J, Breitner JCS, Villeneuve S; PREVENT-AD, HABS, and AIBL Research Groups.
  JAMA Neurol. 2022 Oct 1;79(10):975-985. doi: 10.1001/jamaneurol.2022.2379. PMID: 35907254
• Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults. 
  Meyer PF, Ashton NJ, Karikari TK, Strikwerda-Brown C, Köbe T, Gonneaud J, Pichet Binette A, Ozlen H, Yakoub Y, Simrén J, Pannee J, Lantero-Rodriguez J, Labonté A, Baker SL, Schöll M, Vanmechelen E, Breitner JCS, Zetterberg H, Blennow K, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
  Ann Neurol. 2022 Apr;91(4):548-560. doi: 10.1002/ana.26308. Epub 2022 Feb 18.
  PMID: 35084051
• MSR1 and NEP Are Correlated with Alzheimer’s Disease Amyloid Pathology and Apolipoprotein Alterations. 
  Miron J, Picard C, Labonté A, Auld D, Poirier J; PREVENT-AD research group.
  J Alzheimers Dis. 2022;86(1):283-296. doi: 10.3233/JAD-215410. PMID: 35034907
• Characteristics of subjective cognitive decline associated with amyloid positivity. 
  Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, …, Spiru L; Alzheimer’s Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD research group; Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ.
  Alzheimers Dement. 2022 Oct;18(10):1832-1845. doi: 10.1002/alz.12512. Epub 2021 Dec 8. PMID: 34877782 
• Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease. 
  Picard C, Nilsson N, Labonté A, Auld D, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative; Ashton NJ, Zetterberg H, Blennow K, Breitner JCB, Villeneuve S, Poirier J; PREVENT-AD research group.
  Alzheimers Dement. 2022 May;18(5):875-887. doi: 10.1002/alz.12442. Epub 2021 Sep 29.PMID: 34590423 
• Brain charts for the human lifespan. 
  Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, … Zugman A, Zuo XN; 3R-BRAIN; AIBL; Alzheimer’s Disease Neuroimaging Initiative; Alzheimer’s Disease Repository Without Borders Investigators; CALM Team; Cam-CAN; CCNP; COBRE; cVEDA; ENIGMA Developmental Brain Age Working Group; Developing Human Connectome Project; FinnBrain; Harvard Aging Brain Study; IMAGEN; KNE96; Mayo Clinic Study of Aging; NSPN; POND; PREVENT-AD Research Group; VETSA; Bullmore ET, Alexander-Bloch AF.
  Nature. 2022 Apr;604(7906):525-533. doi: 10.1038/s41586-022-04554-y. Epub 2022 Apr 6. PMID: 35388223 
• Spatial Extent of Amyloid-β Levels and Associations With Tau-PET and Cognition. 
  Ozlen H, Pichet Binette A, Köbe T, Meyer PF, Gonneaud J, St-Onge F, Provost K, Soucy JP, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative, the Harvard Aging Brain Study, the Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease Research Group.
  JAMA Neurol. 2022 Oct 1;79(10):1025-1035. doi: 10.1001/jamaneurol.2022.2442. PMID: 35994280 

• Characteristics of subjective cognitive decline associated with amyloid positivity. 
  Janssen O, Jansen WJ, Vos SJB, Boada M, Parnetti L, Gabryelewicz T, Fladby T, Molinuevo JL, Villeneuve S, Hort J, Epelbaum S, Lleó A, Engelborghs S, van der Flier WM, Landau S, Popp J, Wallin A, Scheltens P, Rikkert MO, Snyder PJ, Rowe C, Chételat G, Ruíz A, Marquié M, Chipi E, Wolfsgruber S, Heneka M, Boecker H, Peters O, Jarholm J, Rami L, Tort-Merino A, Binette AP, Poirier J, Rosa-Neto P, Cerman J, Dubois B, Teichmann M, Alcolea D, Fortea J, Sánchez-Saudinós MB, Ebenau J, Pocnet C, Eckerström M, Thompson L, Villemagne V, Buckley R, Burnham S, Delarue M, Freund-Levi Y, Wallin ÅK, Ramakers I, Tsolaki M, Soininen H, Hampel H, Spiru L; Alzheimer’s Disease Neuroimaging Initiative; FACEHBI study group; PREVENT-AD research group; Tijms B, Ossenkoppele R, Verhey FRJ, Jessen F, Visser PJ.
  Alzheimers Dement. 2022 Oct;18(10):1832-1845. doi: 10.1002/alz.12512. Epub 2021 Dec 8. PMID: 34877782 
• Apolipoprotein B is a novel marker for early tau pathology in Alzheimer’s disease. 
  Picard C, Nilsson N, Labonté A, Auld D, Rosa-Neto P; Alzheimer’s Disease Neuroimaging Initiative; Ashton NJ, Zetterberg H, Blennow K, Breitner JCB, Villeneuve S, Poirier J; PREVENT-AD research group.
  Alzheimers Dement. 2022 May;18(5):875-887. doi: 10.1002/alz.12442. Epub 2021 Sep 29. PMID: 34590423 
• Accelerated functional brain aging in pre-clinical familial Alzheimer’s disease. 
  Gonneaud J, Baria AT, Pichet Binette A, Gordon BA, Chhatwal JP, Cruchaga C, Jucker M, Levin J, Salloway S, Farlow M, Gauthier S, Benzinger TLS, Morris JC, Bateman RJ, Breitner JCS, Poirier J, Vachon-Presseau E, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative (ADNI); Dominantly Inherited Alzheimer Network (DIAN) Study Group; Pre-symptomatic Evaluation of Experimental or Novel Treatments for Alzheimer’s Disease (PREVENT-AD) Research Group.
  Nat Commun. 2021 Sep 9;12(1):5346. doi: 10.1038/s41467-021-25492-9. PMID: 34504080 
• Open science datasets from PREVENT-AD, a longitudinal cohort of pre-symptomatic Alzheimer’s disease. 
  Tremblay-Mercier J, Madjar C, Das S, Pichet Binette A, Dyke SOM, Étienne P, Lafaille-Magnan ME, Remz J, Bellec P, Louis Collins D, Natasha Rajah M, Bohbot V, Leoutsakos JM, Iturria-Medina Y, Kat J, Hoge RD, Gauthier S, Tardif CL, Mallar Chakravarty M, Poline JB, Rosa-Neto P, Evans AC, Villeneuve S, Poirier J, Breitner JCS; PREVENT-AD Research Group.
  Neuroimage Clin. 2021;31:102733. doi: 10.1016/j.nicl.2021.102733. Epub 2021 Jun 17. PMID: 34192666 
• Bundle-specific associations between white matter microstructure and Aβ and tau pathology in preclinical Alzheimer’s disease. 
  Pichet Binette A, Theaud G, Rheault F, Roy M, Collins DL, Levin J, Mori H, Lee JH, Farlow MR, Schofield P, Chhatwal JP, Masters CL, Benzinger T, Morris J, Bateman R, Breitner JC, Poirier J, Gonneaud J, Descoteaux M, Villeneuve S; DIAN Study Group; PREVENT-AD Research Group.
  Elife. 2021 May 13;10:e62929. doi: 10.7554/eLife.62929. PMID: 33983116 
• Generalization of memory-related brain function in asymptomatic older women with a family history of late onset Alzheimer’s Disease: Results from the PREVENT-AD Cohort. 
  Rabipour S, Rajagopal S, Pasvanis S; PREVENT-AD Research Group; Rajah MN.
  Neurobiol Aging. 2021 Aug;104:42-56. doi: 10.1016/j.neurobiolaging.2021.03.009. Epub 2021 Apr 1. PMID: 33964608
• Sex differences in brain aging among adults with family history of Alzheimer’s disease and APOE4 genetic risk. 
  Subramaniapillai S, Rajagopal S, Snytte J, Otto AR; PREVENT-AD Research Group; Einstein G, Rajah MN.
  Neuroimage Clin. 2021;30:102620. doi: 10.1016/j.nicl.2021.102620. Epub 2021 Mar 10. PMID: 33857772 
• Vascular risk factors are associated with a decline in resting-state functional connectivity in cognitively unimpaired individuals at risk for Alzheimer’s disease: Vascular risk factors and functional connectivity changes. 
  Köbe T, Binette AP, Vogel JW, Meyer PF, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
  Neuroimage. 2021 May 1;231:117832. doi: 10.1016/j.neuroimage.2021.117832. Epub 2021 Feb 4. PMID: 33549747
• The impact of demographic, clinical, genetic, and imaging variables on tau PET status. 
  Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD research group; Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O.
  Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2245-2258. doi: 10.1007/s00259-020-05099-w. Epub 2020 Nov 19. PMID: 33215319 
• Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer’s Disease. 
  Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group.
  Biol Psychiatry. 2021 Apr 15;89(8):776-785. doi: 10.1016/j.biopsych.2020.01.023. Epub 2020 Feb 6. PMID: 32228870 
• Association of a Total Cholesterol Polygenic Score with Cholesterol Levels and Pathological Biomarkers across the Alzheimer’s Disease Spectrum. 
  Nilsson NIV, Picard C, Labonté A, Köbe T, Meyer PF, Villeneuve S, Auld D, Poirier J, For The Prevent-Ad Research Group, Alzheimer’s Disease Neuroimaging Initiative.
  Genes (Basel). 2021 Nov 17;12(11):1805. doi: 10.3390/genes12111805. PMID: 34828411 
• CSF apolipoprotein B levels predict future visuospatial cognitive decline and synaptic pathology in healthy elderly with a parental history of Alzheimer’s disease.
  Poirier J., Nilsson N., Labonté, A., Auld D., Rosa Neto, P., Ashton N., Blennow K, Zetterberg, H, the Alzheimer’s Disease Neuroimaging Initiative, Breitner JCB, Villeneuve S., Picard C. for the PREVENT-AD research group. Alzheimer and Dementia, 17, e050342, 31 December 2021.

• The impact of demographic, clinical, genetic, and imaging variables on tau PET status. 
  Ossenkoppele R, Leuzy A, Cho H, Sudre CH, Strandberg O, Smith R, Palmqvist S, Mattsson-Carlgren N, Olsson T, Jögi J, Stormrud E, Ryu YH, Choi JY; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD research group; Boxer AL, Gorno-Tempini ML, Miller BL, Soleimani-Meigooni D, Iaccarino L, La Joie R, Borroni E, Klein G, Pontecorvo MJ, Devous MD Sr, Villeneuve S, Lyoo CH, Rabinovici GD, Hansson O.
  Eur J Nucl Med Mol Imaging. 2021 Jul;48(7):2245-2258. doi: 10.1007/s00259-020-05099-w. Epub 2020 Nov 19. PMID: 33215319 
• Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease. 
  Gonneaud J, Bedetti C, Pichet Binette A, Benzinger TLS, Morris JC, Bateman RJ, Poirier J, Breitner JCS, Villeneuve S; DIAN Study Group and the PREVENT-AD Research Group.
  Neurology. 2020 Sep 15;95(11):e1554-e1564. doi: 10.1212/WNL.0000000000010314. Epub 2020 Aug 5. PMID: 32759192 
• APOE4 Status is Related to Differences in Memory-Related Brain Function in Asymptomatic Older Adults with Family History of Alzheimer’s Disease: Baseline Analysis of the PREVENT-AD Task Functional MRI Dataset. 
  Rabipour S, Rajagopal S, Yu E, Pasvanis S, Lafaille-Magnan ME, Breitner J; PREVENT-AD Research Group; Rajah MN.
  J Alzheimers Dis. 2020;76(1):97-119. doi: 10.3233/JAD-191292. PMID: 32474466 
• Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. 
  Marchant NL, Lovland LR, Jones R, Pichet Binette A, Gonneaud J, Arenaza-Urquijo EM, Chételat G, Villeneuve S; PREVENT-AD Research Group.
  Alzheimers Dement. 2020 Jul;16(7):1054-1064. doi: 10.1002/alz.12116. Epub 2020 Jun 7. PMID: 32508019
• Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer’s Disease. 
  Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group.
  Biol Psychiatry. 2021 Apr 15;89(8):776-785. doi: 10.1016/j.biopsych.2020.01.023. Epub 2020 Feb 6. PMID: 32228870 
• Morphometric network differences in ageing versus Alzheimer’s disease dementia. 
  Pichet Binette A, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.
  Brain. 2020 Feb 1;143(2):635-649. doi: 10.1093/brain/awz414. PMID: 32040564 
• Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. 
  Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
  JAMA Netw Open. 2020 Feb 5;3(2):e1920780. doi: 10.1001/jamanetworkopen.2019.20780. PMID: 32031648
• Intermediate flortaucipir uptake is associated with Aβ-PET and CSF tau in asymptomatic adults. 
  McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, Labonté A, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; PREVENT-AD Research Group.
  Neurology. 2020 Mar 17;94(11):e1190-e1200. doi: 10.1212/WNL.0000000000008905. Epub 2020 Feb 3. PMID: 32015176

• MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan. 
  Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL; PREVENT-AD Research Group; Breitner JCS, Chakravarty MM.
  Hum Brain Mapp. 2019 Dec 15;40(18):5269-5288. doi: 10.1002/hbm.24771. Epub 2019 Aug 26. PMID: 31452289 
• Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study. 
  Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J; PREVENT-AD Research Group.
  PLoS One. 2019 Aug 22;14(8):e0220254. doi: 10.1371/journal.pone.0220254. eCollection 2019. PMID: 31437157 
• Association of PPP2R1A with Alzheimer’s disease and specific cognitive domains. 
  Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J; United Kingdom Brain Expression Consortium; PREVENT-AD research group.
  Neurobiol Aging. 2019 Sep;81:234-243. doi: 10.1016/j.neurobiolaging.2019.06.008. Epub 2019 Jul 2. PMID: 31349112
• No apparent effect of naproxen on CSF markers of innate immune activation. 
  Meyer PF, Labonté A, Rosa-Neto P, Poirier J, Breitner JCS; PREVENT‐AD Research Group.
  Ann Clin Transl Neurol. 2019 Jun 6;6(6):1127-1133. doi: 10.1002/acn3.788. eCollection 2019 Jun. PMID: 31211178 
• Association of TLR4 with Alzheimer’s disease risk and presymptomatic biomarkers of inflammation. 
  Miron J, Picard C, Lafaille-Magnan MÉ, Savard M, Labonté A, Breitner J, Rosa-Neto P, Auld D, Poirier J; PREVENT-AD research group.
  Alzheimers Dement. 2019 Jul;15(7):951-960. doi: 10.1016/j.jalz.2019.03.012. Epub 2019 Jun 4. PMID: 31175027
• INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. 
  Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Magnan ME, Savard M, Rosa-Neto P, Poirier J, Etienne P, Breitner J; PREVENT-AD Research Group.
  Neurology. 2019 Apr 30;92(18):e2070-e2080. doi: 10.1212/WNL.0000000000007232. Epub 2019 Apr 5. PMID: 30952794 
• Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression. 
  Liebsch F, Kulic L, Teunissen C, Shobo A, Ulku I, Engelschalt V, Hancock MA, van der Flier WM, Kunach P, Rosa-Neto P, Scheltens P, Poirier J, Saftig P, Bateman RJ, Breitner J, Hock C, Multhaup G.
  Nat Commun. 2019 May 20;10(1):2240. doi: 10.1038/s41467-019-10152-w. PMID: 31110178 

• Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease. 
  Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.
  Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14. PMID: 29735156
• Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease. 
  Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative* and the PREVENT-AD Research Group.
  Brain. 2018 Jun 1;141(6):1871-1883. doi: 10.1093/brain/awy093. PMID: 29688388 
• Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis. 
  Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group.
  J Alzheimers Dis. 2018;63(2):577-590. doi: 10.3233/JAD-170887. PMID: 29660934
• Proximity to Parental Symptom Onset and Amyloid-β Burden in Sporadic Alzheimer Disease. 
  Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TLS, Johnson SC, Breitner JCS, Poirier J; Presymptomatic Evaluation of Novel or Experimental Treatments for Alzheimer Disease (PREVENT-AD) Research Group.
  JAMA Neurol. 2018 May 1;75(5):608-619. doi: 10.1001/jamaneurol.2017.5135. PMID: 29482212 
• Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer’s disease. 
  Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group.
  Hum Brain Mapp. 2018 Feb;39(2):971-984. doi: 10.1002/hbm.23897. Epub 2017 Nov 21. PMID: 29164798 
• A comparison of publicly available linear MRI stereotaxic registration techniques. 
  Dadar M, Fonov VS, Collins DL; Alzheimer’s Disease Neuroimaging Initiative.
  Neuroimage. 2018 Jul 1;174:191-200. doi: 10.1016/j.neuroimage.2018.03.025. Epub 2018 Mar 13. PMID: 29548850

• Subjective Cognitive Decline Is Associated With Altered Default Mode Network Connectivity in Individuals With a Family History of Alzheimer’s Disease. 
  Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JCS, Villeneuve S; PREVENT-AD Research Group.
  Biol Psychiatry Cogn Neurosci Neuroimaging. 2018 May;3(5):463-472. doi: 10.1016/j.bpsc.2017.11.012. Epub 2017 Dec 14. PMID: 29735156
• Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer’s disease. 
  Tardif CL, Devenyi GA, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group.
  Hum Brain Mapp. 2018 Feb;39(2):971-984. doi: 10.1002/hbm.23897. Epub 2017 Nov 21. PMID: 29164798 
• Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease. 
  Tuwaig M, Savard M, Jutras B, Poirier J, Collins DL, Rosa-Neto P, Fontaine D, Breitner JCS; PREVENT-AD Research Group.
  J Alzheimers Dis. 2017;60(4):1589-1600. doi: 10.3233/JAD-170545. PMID: 28984583 
• Odor identification as a biomarker of preclinical AD in older adults at risk. 
  Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group.
  Neurology. 2017 Jul 25;89(4):327-335. doi: 10.1212/WNL.0000000000004159. Epub 2017 Jun 28. PMID: 28659431 

• ‘Alzheimer’s Progression Score’: Development of a Biomarker Summary Outcome for AD Prevention Trials. 
  Leoutsakos JM, Gross AL, Jones RN, Albert MS, Breitner JCS.
  J Prev Alzheimers Dis. 2016;3(4):229-235. doi: 10.14283/jpad.2016.120. PMID: 29034223 
• Rationale and Structure for a New Center for Studies on Prevention of Alzheimer’s Disease (StoP-AD). 
  Breitner JCS, Poirier J, Etienne PE, Leoutsakos JM.
  J Prev Alzheimers Dis. 2016;3(4):236-242. doi: 10.14283/jpad.2016.121. PMID: 29199324

• Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease. 
  Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group.
  Sci Data. 2015 Oct 13;2:150043. doi: 10.1038/sdata.2015.43. eCollection 2015. PMID: 26504522